According to the 2024 interim results released by Yuanda Pharmaceutical on August 19th, the company achieved a revenue of approximately HKD 6.05 billion in the first half of the year, with a year-on-year growth of approximately 5.4% after excluding the impact of exchange rates; The net profit attributable to the parent company was approximately HKD 1.56 billion, a year-on-year increase of 58.0% after excluding the impact of exchange rates. In terms of specific business, Yuanda Pharmaceutical's nuclear medicine anti-tumor diagnosis and treatment sector achieved a revenue of approximately HKD 210 million, a significant increase of approximately 107.6% year-on-year.

 

 

 

In the first half of this year, Yuanda Pharmaceutical made significant breakthroughs in multiple fields such as nuclear medicine and innovative drugs, demonstrating its strong research and development capabilities and market competitiveness. In the first half of this year, Yuanda Pharmaceutical achieved 33 major milestones, including 15 innovative products. During the period, the profits of Yuanda Pharmaceutical's nuclear medicine sector continued to be realized.

 

 

 

It is reported that the company continues to promote the heavyweight innovative product Yigantai ® The promotion of yttrium [90Y] microsphere injection has been completed by nearly 70 hospitals, and over 140 physicians have obtained Yigantai ® Surgical physicians have registered, and formal surgeries have been carried out in more than 40 hospitals in 22 provinces and cities. Meanwhile, Yi Gantai ® We have entered 40 welfare insurance and 2 special drug insurance, covering 20 provinces and 27 cities.

 

 

 

The nuclear medicine sector is one of the core innovative areas of Yuanda Pharmaceutical. The so-called nuclear drugs refer to drugs containing medical isotopes, which can produce metal or non-metal elements of alpha, beta, or gamma radiation, destroy cell chromosomes, stop cell growth, and eliminate proliferating cancer cells. The prospects of the nuclear medicine market are broad, with data predicting that by 2030, the global nuclear medicine market will reach about 30 billion US dollars, equivalent to over 210 billion yuan.

 

 

 

In recent years, Yuanda Pharmaceutical has continued to deepen its cultivation in the field of nuclear medicine, building tumor intervention technology platforms and RDC technology platforms. It is reported that in addition to the above-mentioned Yigantai ® In addition to yttrium [90Y] microsphere injection, Yuanda Pharmaceutical has also made layout in the field of RDC (Radiodiagnostic and Therapeutic Drugs). At present, the company has a total of 12 innovative drugs in reserve, covering 5 radioactive isotopes including 68Ga, 177Lu, 131I, 90Y, and 89Zr, and covering 7 types of cancer including liver cancer, prostate cancer, and brain cancer. From the perspective of research and development progress, Yuanda Pharmaceutical currently has 4 innovative RDCs approved for clinical trials in China, of which 3 have entered phase III clinical trials.

 

 

 

It is reported that in the first half of this year, Yuanda Pharmaceutical's nuclear drug research pipeline also made multiple advances, such as the innovative radionuclide conjugate drug (RDC) TLX250 CDx for diagnosing clear cell renal cell carcinoma (ccRCC), which completed phase I clinical trials in China and smoothly entered confirmatory clinical research; The innovative RDC product ITM-11 for the treatment of gastrointestinal pancreatic neuroendocrine tumors (GEP NETs) has been approved for Phase III clinical trials in China; In addition, globally innovative temperature sensitive embolic agents have entered the stage of registered clinical trials

 

 

 

In addition to nuclear medicine, Yuanda Pharmaceutical has also deepened its industrial layout in the areas of cardiovascular and cerebrovascular emergency treatment and facial features. During the reporting period, Yuanda Pharmaceutical achieved a 100% equity change registration in Tianjin Tianbian Pharmaceutical Co., Ltd. in the cardiovascular and cerebrovascular emergency sector, rapidly entering the chronic disease market. In the field of facial recognition, Yuanda Pharmaceutical has acquired 90% equity of Chongqing Duoputai Pharmaceutical Technology Co., Ltd. and obtained the rights to the national medical insurance and essential drug catalog variety Maixuekang series products.